Navigation Links
ViroPharma Announces Discontinuation of HCV-796 Development
Date:4/16/2008

EXTON, Pa., April 16 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) announced today that ViroPharma and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), have jointly discontinued the development of HCV-796 due to the previously announced safety issue that emerged in the ongoing Phase 2 trial in patients with hepatitis C.

"Clearly, this is a disappointing outcome for patients suffering from this difficult disease," commented Vincent Milano, ViroPharma's president and chief executive officer. "Significant activities were undertaken to determine a clear path forward for HCV-796; however, the risk associated with potential hepatotoxicity ultimately posed too high of a hurdle to merit further development."

The companies will ensure that patients enrolled in the ongoing Phase 2 study will continue to receive the current standard of care. ViroPharma also announced that ViroPharma and Wyeth do not expect to continue to collaborate on future development of hepatitis C treatment candidates.

About ViroPharma Incorporated

ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 The Competitive Intelligence (CI) function ... changes. CI leaders who adjust will succeed, and those ... new Best Practices, LLC study CI leaders from 32 ... - Use secondary research whenever possible - ... - Internal staff who are creative thinkers provide ...
(Date:8/29/2014)... Aug. 29, 2014 Pomerantz LLP has filed ... the "Company") (NASDAQ: EDAP ) and certain ... States District Court, Southern District of New ... behalf of a class consisting of all persons or ... and July 30, 2014, inclusive (the "Class Period"). This class ...
(Date:8/29/2014)... Aug. 29, 2014   Mast Therapeutics, Inc. ... announced today that Santosh Vetticaden, Chief Medical Officer ... Company, for personal reasons, in mid-September.  Edwin ... of Aires Pharmaceuticals, which Mast acquired earlier this ... the Company,s interim Chief Medical Officer.  Dr. Parsley ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4
... Md., Jan. 31, 2011 Vanda Pharmaceuticals Inc. (Vanda) ... on the development and commercialization of products for central ... a universal shelf registration statement on Form S-3 with ... effective by the SEC, the shelf registration statement will ...
... Technologies, Inc. (the "Company") (Nasdaq: CMED ), ... announced that it will report its unaudited financial results ... before the U.S. market opens on February 18, 2011. ... 2011. The Company,s senior management will ...
Cached Medicine Technology:Vanda Pharmaceuticals Files Shelf Registration Statement 2Vanda Pharmaceuticals Files Shelf Registration Statement 3Vanda Pharmaceuticals Files Shelf Registration Statement 4China Medical Technologies to Announce Results for the Third Fiscal Quarter Ended December 31, 2010 on February 18, 2011 2
(Date:8/30/2014)... New York, NY (PRWEB) August 30, 2014 ... headlines will quickly ensue, as happened on Wednesday, August 27th, ... a successful attack on JPMorgan Chase & Co and ... that the FBI is actually investigating attacks on seven ... and how they may be affected, and the buzz quickly ...
(Date:8/30/2014)... As 500 Zoloft lawsuits pending ligation contend the SSRI andidepressant ... & Schulte LLC recently learned of a remand issued by ... in the Zoloft lawsuits was granted to 25 plaintiffs ... one SSRI lawsuit filed jointly under MDL 2342 ... sent back to the Missouri state court in which it ...
(Date:8/30/2014)... 30, 2014 Barton Associates, an industry ... tenens company , announces a new office location in ... Associates is headquartered in Peabody, MA, with additional staffing ... TX; and Jupiter, FL. , Barton Associates made the ... physician shortage crisis affecting the United States, a crisis ...
(Date:8/30/2014)... Spain Saturday 30 August 2014: The first ... patients with acute coronary syndromes (ACS) are published ... position paper was written jointly by the European ... Association (ACCA) and the European Association of Percutaneous ... , Professor Bulent Gorenek (Turkey), chairperson of the ...
(Date:8/30/2014)... Spain Saturday 30 August 2014: A new ... (HCM) identifies candidates for implantable cardioverter defibrillators (ICDs) ... at ESC Congress by Task Force Chairperson Professor ... on Diagnosis and Management of Hypertrophic Cardiomyopathy" are ... Journal (1) and on the ESC Website. ...
Breaking Medicine News(10 mins):Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 2Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 3Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 4Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 5Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 2Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 3Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 4Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 5Health News:Barton Associates to Open a New Office Location in Keene, NH 2Health News:First multidisciplinary recommendations on management of arrhythmias in ACS patients 2Health News:Sudden death predictor identifies ICD candidates in new ESC Guidelines 2
... ... to help anyone seeking improved health and wellness. Learn how to improve the look and ... enhance your physical appearance with information provided on this new Web site. , ... (PRWEB) June 17, 2010 -- A new Web site has ...
... , ... to announce the addition of Lázaro Garza as an Engineered Sales Representative for Ellsworth Adhesives ... ... announce the addition of Lázaro Garza as an Engineered Sales Representative for Ellsworth Adhesives S. ...
... Italy, Thursday 17 June 2010: Smoking cigarettes is a ... may have a negative impact on the effectiveness of ... these treatments, according to results of two studies presented ... European League Against Rheumatism in Rome, Italy. A further ...
... ... in 2010 Focusing on Professional, Olympic, and Recreational Athletes , ... Washington, D.C. (PRWEB) June 17, 2010 -- Athletes for Hope ... Agassi, Muhammad Ali, and Lance Armstrong for the purpose of inspiring all athletes to engage ...
... ... Receives Seal of Approval from Industry Voice , ... Fishkill, NY (PRWEB) June 17, 2010 -- Dear ... dentistry and oral health, has announced that the International Congress of Oral Implantologists ...
... ... released Semantics Platform v 2.0 which is made up of three products: Semantics.Datacenter, Semantics.Server, ... product offerings in industry standard benchmark tests (Berlin 100M 5/25/10). , ... Brattleboro, VT (PRWEB) June ...
Cached Medicine News:Health News:New Web Site Provides Helpful Exercise and Nutrition Tips 2Health News:Ellsworth Adhesives Announces New International Engineered Sales Representative 2Health News:Smoking cigarettes is a predictor of RA and may negatively impact on efficacy of anti-TNFs 2Health News:Smoking cigarettes is a predictor of RA and may negatively impact on efficacy of anti-TNFs 3Health News:Athletes for Hope Awarded $2 Million Grant by Kellogg Foundation 2Health News:Athletes for Hope Awarded $2 Million Grant by Kellogg Foundation 3Health News:International Congress of Oral Implantologists (ICOI) Joins Other Professional Organizations Endorsing Dear Doctor Magazine 2Health News:Intellidimension Releases New Version of Semantic Web Technologies 2
... a combination of innovative design, consistently reliable ... I-125 implant an ideal choice for your ... every BrachySource I-125 implant order is backed ... required by clinicians who must meet the ...
... BrachySource iodine-125 implant is a combination of ... visibility that makes BrachySource I-125 implant an ... can be confident that every BrachySource I-125 ... management services which is required by clinicians ...
The silicone Tractfinder provides excellent fluoroscopic visualization. Manipulation of the movable core guidewire flexes the tapered proximal tip for maximum control in negotiating a tortuous ureter...
... Used for temporary internal drainage from the ... of a stricture. The segment with no ... lumen while preventing ingrowth of the ureteral ... peel-open packages. Intended for one-time use. CAUTION: ...
Medicine Products: